KACEY PHILLIPS: Open Payments
NPI 1629712310 · HATTIESBURG, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,344 in 60 payments from 19 companies in 2025. Trend: 2023 $256 · 2024 $773 · 2025 $1,344
Food & beverage: $1,264Education: $80
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 11 | $276 |
| Novartis Pharmaceuticals Corporation | 15 | $273 |
| Galderma Laboratories, L.P. | 2 | $146 |
| GlaxoSmithKline, LLC. | 6 | $106 |
| AstraZeneca Pharmaceuticals LP | 5 | $103 |
| CSL Behring | 4 | $89 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $79 |
| Boston Scientific Corporation | 2 | $31 |
| E.R. Squibb & Sons, L.L.C. | 2 | $29 |
| AtriCure, Inc. | 1 | $26 |
Products named: DUPIXENT, LEQVIO, NEMLUVIO, NUCALA, NEFFY, TEZSPIRE, Andembry, Haegarda.
Industry payments across MS — which companies pay providers there.
